| Locorregional relapse | Metastatic relapse | |||
---|---|---|---|---|---|
1L | 2L | 3L | 4L +  | ||
a Health resource (percentage of patients | |||||
ED visits | 30.0% | 38.6% | 51.4% | 61.4% | 64.3% |
Hospitalizations | 17.1% | 21.3% | 35.0% | 45.0% | 55.7% |
Visit to day hospital | 55.7% | 71.9% | 85.7% | 77.1% | 65.7% |
Specialist visits | 100.0% | 87.5% | 100.0% | 98.6% | 97.1% |
Laboratory analysis | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% |
Bone scintigraphy | 13.6% | 20.0% | 17.9% | 19.3% | 17.1% |
PET/CT-scan | 35.0% | 11.4% | 7.1% | 5.7% | 4.3% |
Bone X-ray | 27.3% | 45.7% | 52.9% | 52.9% | 58.6% |
Nuclear magnetic resonance | 43.6% | 27.9% | 34.3% | 32.1% | 27.1% |
CT scan (Brain) | 0.0% | 14.3% | 14.3% | 14.3% | 14.3% |
CT scan (Others) | 97.1% | 99.3% | 99.3% | 99.3% | 97.1% |
b) Health resource (annual frequency) | |||||
ED visits | 2.0 | 2.4 | 2.9 | 3.6 | 3.7 |
Hospitalizations | 5.3 | 5.1 | 6.6 | 7.6 | 8.6 |
Visit to day hospital (oral / IV treatments) | 6.4 / 17.0 | 12.0/17.0 | 12.0/17.0 | 12.0 / 17.0 | 12.0 / 17.0 |
Specialist visits (oral / IV treatments) | 6.4/ 17.0 | 12.0/17.0 | 12.0/17.0 | 12.0 / 17.0 | 12.0 / 17.0 |
Laboratory analysis (oral / IV treatments) | 6.4/ 17.0 | 12.0/17.0 | 12.0/17.0 | 12.0/17.0 | 12.0/17.0 |
Bone scintigraphy | 1.2 | 1.7 | 1.4 | 1.5 | 1.3 |
PET/CT-scan | 1.0 | 0.7 | 0.7 | 0.6 | 0.4 |
Bone X-ray | 2.6 | 2.4 | 2.9 | 2.6 | 3.2 |
Nuclear magnetic resonance | 1.7 | 2.3 | 1.7 | 1.9 | 1.6 |
CT scan (Brain) | 0.0 | 0.4 | 0.4 | 0.4 | 0.4 |
CT scan (Others) | 3.7 | 4.1 | 4.1 | 3.9 | 4.0 |